Altimmune, Inc. Presents New Data on Pemvidutide's Effects on Inflammatory Lipids for Metabolic Dysfunction-Associated Steatotic Liver Disease at The Liver Meeting® 2024.
Altimmune, Inc. shared new data from its Phase 1b trial of pemvidutide, showing significant reductions in inflammatory lipids related to cardiovascular issues, supporting its potential benefits for metabolic dysfunction-associated liver conditions.
Company Information
Company
Altimmune
Location
910 Clopper Rd
Gaithersburg, Maryland, United States
About
Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH), Alcohol Use Disorder (AUD), Alcohol-associated Liver Disease (ALD) and obesity.
Fundz sees it the moment Altimmune ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
GaithersburgBiotechnologyHealth CareTherapeuticsBiopharmaresearch